Clinical characteristics and outcomes of allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational cohort study.

Publication date: Feb 21, 2024

We aimed to describe the clinical characteristics, particularly the occurrence and risk factors of severe/critical illness, in allogeneic hematopoietic stem cell (allo-HSCT) recipients infected with coronavirus disease 2019 (COVID-19) caused by Omicron variant in an observational prospective study (n = 311). The median time from allo-HSCT to COVID-19 diagnosis was 8. 5 months (range 0. 8-106. 1) months. Four patients (1. 3%) were reported to be asymptomatic during Omicron variant infection, and 135 (43. 4%) patients showed lower respiratory tract disease. Thirty-four (10. 9%) patients were categorized into serious infection (severe illness n = 25; critical illness n = 9) and the median duration from COVID-19 diagnosis to serious infections was 6 days (range, 0-29) days. Thirteen (4. 2%) and 6 (1. 9%) patients required intensive care unit care and invasive mechanical ventilation, respectively. Receiving more than 1 type of immunosuppressive therapies at COVID-19 diagnosis was associated with severity and persistence of infection. Six patients (1. 9%) died after diagnosis of COVID-19 infection. The 4-week probability of overall survival after COVID-19 diagnosis was 98. 7%, which was 100% and 88. 2% for non-serious and serious infection group (P 

Concepts Keywords
6days Coronavirus disease 2019
Coronavirus Mortality
Hematopoietic Omicron variant
Immunosuppressive Severity


Type Source Name
disease IDO cell
disease MESH coronavirus disease 2019
disease MESH critical illness
disease VO time
disease MESH infection
disease MESH Long Covid

Original Article

(Visited 1 times, 1 visits today)